+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The prevalence of encephalomyocarditis virus neutralizing antibodies among various human populations

American Journal of Tropical Medicine and Hygiene 27(1 Pt 1): 144-149

The prevalence of encephalomyocarditis virus neutralizing antibodies among various human populations

The prevalence of encephalomyocarditis virus (EMC) antibodies among selected human populations in various regions of the world was determined by the plaque reduction neutralization method. Antibody rates among children ranged from 1.0 to 33.9%, while those among adults varied from 3.2 to 50.6%. No differences between sexes were found in the frequency of EMC infection. The pattern of age-specific antibody rates observed among the study populations suggests that EMC infection occurs primarily during childhood. There appeared to be no association between the presence of EMC antibodies and potential exposure to rats. Sera from diabetic, suspected encephalitis, and myocarditis patients were also examined for EMC neutralizing antibodies. The prevalence of antibodies among these groups was not significantly different from that of control populations in the same geographic regions. No association was demonstrated between EMC infection and these three diseases. The results of this study indicate that EMC infection in man is fairly common but that most human cases are probably asymptomatic and/or unrecognized.

Accession: 006740327

PMID: 204206

Related references

Jonkers, A.H., 1961: Serosurvey of encephalomyocarditis virus neutralizing antibodies in southern Louisiana and Peruvian Indian populations. Sera of 947 members of 169 southern Louisiana households and of 955 Peruvian Indians from the Andean highlands were examined for the presence of encephalomycarditis virus neutralizing antibodies. The testing was done with 14 diluted serum against...

Vlaspolder, F.; Harmsen, T.; van Veenendaal, D.; Kraaijeveld, C.A.; Snippe, H., 1988: Application of immunoassay of encephalomyocarditis virus in cell culture with enzyme-labeled virus-specific monoclonal antibodies for rapid detection of virus, neutralizing antibodies, and interferon. Encephalomyocarditis virus (EMCV)-specific monoclonal antibody UM 21.1 labeled with horseradish peroxidase was used to detect EMCV in L-cell monolayers. This direct enzyme immunoassay of EMCV, performed in wells of 96-well plates, could be applied...

Vlaspolder, F.; Kraaijeveld, C.A.; Oosterlaken, T.; van Buuren, R.; Benaissa-Trouw, B.J.; Snippe, H., 1988: Discrimination of determinant specificity of two encephalomyocarditis virus neutralizing monoclonal antibodies by competition, mixed neutralization and anti-idiotypic antibodies. To investigate the epitope(s) on encephalomyocarditis virus (EMCV) involved in neutralization, two neutralizing monoclonal antibodies (MAs) (MA UM 21.1 and MA UM 21.2) were tested in a competition binding assay (CBA), a mixed neutralization test a...

Harmsen, M.; Oosterlaken, T.A.; Tangerman, C.; Snippe, H.; Kraaijeveld, C.A., 1993: Detection by a solid phase independent enzyme immunoassay of monoclonal anti-idiotypic antibodies against monoclonal antibodies neutralizing Semliki Forest virus and encephalomyocarditis virus. Neutralization inhibition enzyme immunoassay (NI-EIA) was evaluated for its usefulness to detect monoclonal anti-idiotypic antibodies (ab2mAbs) against idiotypic monoclonal antibodies (ab1mAbs) neutralizing either Semliki Forest virus (SFV) or enc...

Smith, A.W.; Akers, T.G.; Prato, C.M.; Bray, H., 1976: Prevalence and distribution of 4 serotypes of san miguel sea lion virus serum neutralizing antibodies in wild animal populations. Serum neutralizing antibodies to 4 serotypes of San Miguel Sea Lion Virus (SMSV) were demonstrated in a variety of marine and terrestrial species. These results show a wide geographic distribution of SMSV in the marine environment and indicate tha...

Barlough J.E.; Berry E.S.; Skilling D.E.; Smith A.W., 1988: Prevalence and distribution of serum neutralizing antibodies to san miguel sea lion virus types 6 and 7 in selected populations of marine mammals. Neutralizing antibodies to San Miguel sea lion virus (SMSV) types 6 and/or 7 were found in sera collected from California sea lions Zalophus c. californianus in 1977 and 1983, and sera collected from Steller sea lions Eumetopias jubatus in 1976 an...

Neal, Z.C.; Splitter, G.A., 1998: Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies. Although the ability of serum-neutralizing antibodies to protect against picornavirus infection is well established, the contribution of cell-mediated immunity to protection is uncertain. Using major histocompatibility complex class II-deficient (...

Hara, H.; Hara, H.; Hironaka, T.; Inoue, M.; Iida, A.; Shu, T.; Hasegawa, M.; Nagai, Y.; Falsey, A.R.; Kamali, A.; Anzala, O.; Sanders, E.J.; Karita, E.; Mwananyanda, L.; Vasan, S.; Lombardo, A.; Parks, C.L.; Sayeed, E.; Krebs, M.; Cormier, E.; Ackland, J.; Price, M.A.; Excler, J-Louis., 2011: Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to dete...

Halbert, C.L.; Miller, A.Dusty.; McNamara, S.; Emerson, J.; Gibson, R.L.; Ramsey, B.; Aitken, M.L., 2006: Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Adeno-associated virus ( AAV) vectors are promising candidates for gene therapy directed to the lungs, in particular for treatment of cystic fibrosis (CF). In animal models of lung gene transfer, neutralizing antibodies in serum made in response t...

Tesh, R.B.; Gajdusek, D.C.; Garruto, R.M.; Cross, J.H.; Rosen, L., 1975: The distribution and prevalence of group A arbovirus neutralizing antibodies among human populations in Southeast Asia and the Pacific islands. Plaque reduction neutralization tests, using five group A arboviruses (chikungunya, Ross River, Getah, Bebaru and Sindbis), were done on sera from human populations in 44 Southeast Asia and Pacific island localities. Specificity of the plaque neut...